nodes	percent_of_prediction	percent_of_DWPC	metapath
Pazopanib—KDR—esophageal cancer	0.395	0.821	CbGaD
Pazopanib—ABCB1—esophageal cancer	0.0859	0.179	CbGaD
Pazopanib—ABCG2—Carboplatin—esophageal cancer	0.0259	0.277	CbGbCtD
Pazopanib—ABCG2—Cisplatin—esophageal cancer	0.0222	0.236	CbGbCtD
Pazopanib—SLCO1B1—Methotrexate—esophageal cancer	0.0181	0.193	CbGbCtD
Pazopanib—ABCG2—Methotrexate—esophageal cancer	0.0144	0.153	CbGbCtD
Pazopanib—ABCB1—Cisplatin—esophageal cancer	0.00799	0.0852	CbGbCtD
Pazopanib—ABCB1—Methotrexate—esophageal cancer	0.00519	0.0553	CbGbCtD
Pazopanib—Rilpivirine—NR1I2—esophageal cancer	0.00481	0.858	CrCbGaD
Pazopanib—MAP3K9—epithelium—esophageal cancer	0.00237	0.0214	CbGeAlD
Pazopanib—FGFR2—exocrine gland—esophageal cancer	0.00211	0.0191	CbGeAlD
Pazopanib—ITK—bronchus—esophageal cancer	0.00192	0.0174	CbGeAlD
Pazopanib—MAP3K9—digestive system—esophageal cancer	0.0018	0.0163	CbGeAlD
Pazopanib—TAOK1—bronchus—esophageal cancer	0.00175	0.0159	CbGeAlD
Pazopanib—SH2B3—bronchus—esophageal cancer	0.00165	0.0149	CbGeAlD
Pazopanib—MAP3K9—lung—esophageal cancer	0.0015	0.0136	CbGeAlD
Pazopanib—SH2B3—trachea—esophageal cancer	0.00148	0.0134	CbGeAlD
Pazopanib—KIT—exocrine gland—esophageal cancer	0.00146	0.0133	CbGeAlD
Pazopanib—FGF1—neck—esophageal cancer	0.00143	0.0129	CbGeAlD
Pazopanib—FGFR3—epithelium—esophageal cancer	0.0014	0.0127	CbGeAlD
Pazopanib—BMPR1B—epithelium—esophageal cancer	0.00139	0.0126	CbGeAlD
Pazopanib—FGFR3—bronchus—esophageal cancer	0.00138	0.0125	CbGeAlD
Pazopanib—BMPR1B—bronchus—esophageal cancer	0.00137	0.0124	CbGeAlD
Pazopanib—FGFR2—neck—esophageal cancer	0.00135	0.0122	CbGeAlD
Pazopanib—FLT1—neck—esophageal cancer	0.00125	0.0113	CbGeAlD
Pazopanib—ITK—lung—esophageal cancer	0.00124	0.0112	CbGeAlD
Pazopanib—STK36—bronchus—esophageal cancer	0.00124	0.0112	CbGeAlD
Pazopanib—PI4KB—bronchus—esophageal cancer	0.00122	0.0111	CbGeAlD
Pazopanib—LIMK2—bronchus—esophageal cancer	0.0012	0.0108	CbGeAlD
Pazopanib—PI4KB—smooth muscle tissue—esophageal cancer	0.00119	0.0108	CbGeAlD
Pazopanib—TAOK1—lung—esophageal cancer	0.00113	0.0102	CbGeAlD
Pazopanib—STK36—trachea—esophageal cancer	0.00111	0.0101	CbGeAlD
Pazopanib—PI4KB—trachea—esophageal cancer	0.0011	0.00992	CbGeAlD
Pazopanib—FLT4—epithelium—esophageal cancer	0.00109	0.0099	CbGeAlD
Pazopanib—STK16—digestive system—esophageal cancer	0.00108	0.0098	CbGeAlD
Pazopanib—LIMK2—trachea—esophageal cancer	0.00108	0.00974	CbGeAlD
Pazopanib—PIP4K2C—bronchus—esophageal cancer	0.00107	0.0097	CbGeAlD
Pazopanib—SH2B3—lung—esophageal cancer	0.00106	0.00963	CbGeAlD
Pazopanib—FGFR1—bronchus—esophageal cancer	0.00106	0.00962	CbGeAlD
Pazopanib—KDR—neck—esophageal cancer	0.00106	0.00956	CbGeAlD
Pazopanib—MAP3K9—lymph node—esophageal cancer	0.00103	0.00932	CbGeAlD
Pazopanib—FGF1—epithelium—esophageal cancer	0.000971	0.00879	CbGeAlD
Pazopanib—PIP4K2C—trachea—esophageal cancer	0.000961	0.00871	CbGeAlD
Pazopanib—PLK4—lung—esophageal cancer	0.000957	0.00867	CbGeAlD
Pazopanib—LCK—bronchus—esophageal cancer	0.00095	0.00861	CbGeAlD
Pazopanib—KIT—neck—esophageal cancer	0.000936	0.00847	CbGeAlD
Pazopanib—FGF1—smooth muscle tissue—esophageal cancer	0.000936	0.00847	CbGeAlD
Pazopanib—FGFR2—epithelium—esophageal cancer	0.000917	0.0083	CbGeAlD
Pazopanib—PDGFRB—neck—esophageal cancer	0.000914	0.00828	CbGeAlD
Pazopanib—STK16—lung—esophageal cancer	0.000904	0.00819	CbGeAlD
Pazopanib—FGFR3—lung—esophageal cancer	0.00089	0.00806	CbGeAlD
Pazopanib—RIOK2—lung—esophageal cancer	0.00089	0.00806	CbGeAlD
Pazopanib—FGFR2—smooth muscle tissue—esophageal cancer	0.000884	0.008	CbGeAlD
Pazopanib—MAP3K19—lung—esophageal cancer	0.000881	0.00798	CbGeAlD
Pazopanib—BMPR1B—lung—esophageal cancer	0.000881	0.00798	CbGeAlD
Pazopanib—LCK—trachea—esophageal cancer	0.000853	0.00773	CbGeAlD
Pazopanib—FLT1—epithelium—esophageal cancer	0.00085	0.0077	CbGeAlD
Pazopanib—ITK—lymph node—esophageal cancer	0.000849	0.00768	CbGeAlD
Pazopanib—FLT1—bronchus—esophageal cancer	0.000837	0.00758	CbGeAlD
Pazopanib—EPHB6—bronchus—esophageal cancer	0.000827	0.00749	CbGeAlD
Pazopanib—FLT1—smooth muscle tissue—esophageal cancer	0.000819	0.00742	CbGeAlD
Pazopanib—STK36—lung—esophageal cancer	0.000799	0.00724	CbGeAlD
Pazopanib—Rilpivirine—ABCB1—esophageal cancer	0.000794	0.141	CrCbGaD
Pazopanib—STK10—bronchus—esophageal cancer	0.000792	0.00718	CbGeAlD
Pazopanib—TAOK3—bronchus—esophageal cancer	0.000789	0.00715	CbGeAlD
Pazopanib—PI4KB—lung—esophageal cancer	0.000787	0.00713	CbGeAlD
Pazopanib—LIMK2—lung—esophageal cancer	0.000773	0.007	CbGeAlD
Pazopanib—TAOK1—lymph node—esophageal cancer	0.000772	0.007	CbGeAlD
Pazopanib—PDGFRA—smooth muscle tissue—esophageal cancer	0.000767	0.00695	CbGeAlD
Pazopanib—FLT1—trachea—esophageal cancer	0.000752	0.00681	CbGeAlD
Pazopanib—EPHB6—trachea—esophageal cancer	0.000743	0.00673	CbGeAlD
Pazopanib—FGF1—digestive system—esophageal cancer	0.000739	0.00669	CbGeAlD
Pazopanib—SH2B3—lymph node—esophageal cancer	0.000727	0.00659	CbGeAlD
Pazopanib—KDR—epithelium—esophageal cancer	0.000718	0.00651	CbGeAlD
Pazopanib—AURKC—lymph node—esophageal cancer	0.000716	0.00648	CbGeAlD
Pazopanib—TAOK3—trachea—esophageal cancer	0.000709	0.00642	CbGeAlD
Pazopanib—MAP2K5—bronchus—esophageal cancer	0.000708	0.00641	CbGeAlD
Pazopanib—KDR—bronchus—esophageal cancer	0.000708	0.00641	CbGeAlD
Pazopanib—PDGFRA—trachea—esophageal cancer	0.000704	0.00638	CbGeAlD
Pazopanib—FGFR2—digestive system—esophageal cancer	0.000698	0.00632	CbGeAlD
Pazopanib—FLT4—lung—esophageal cancer	0.000695	0.00629	CbGeAlD
Pazopanib—KDR—smooth muscle tissue—esophageal cancer	0.000692	0.00627	CbGeAlD
Pazopanib—PIP4K2C—lung—esophageal cancer	0.000691	0.00626	CbGeAlD
Pazopanib—CSF1R—bronchus—esophageal cancer	0.000691	0.00625	CbGeAlD
Pazopanib—FGFR1—lung—esophageal cancer	0.000685	0.00621	CbGeAlD
Pazopanib—CSF1R—smooth muscle tissue—esophageal cancer	0.000676	0.00612	CbGeAlD
Pazopanib—MAP3K2—lung—esophageal cancer	0.000655	0.00593	CbGeAlD
Pazopanib—PLK4—lymph node—esophageal cancer	0.000655	0.00593	CbGeAlD
Pazopanib—FLT1—digestive system—esophageal cancer	0.000647	0.00586	CbGeAlD
Pazopanib—KIT—epithelium—esophageal cancer	0.000637	0.00577	CbGeAlD
Pazopanib—KDR—trachea—esophageal cancer	0.000635	0.00575	CbGeAlD
Pazopanib—MAP2K5—trachea—esophageal cancer	0.000635	0.00575	CbGeAlD
Pazopanib—KIT—bronchus—esophageal cancer	0.000627	0.00568	CbGeAlD
Pazopanib—PDGFRB—epithelium—esophageal cancer	0.000622	0.00563	CbGeAlD
Pazopanib—CSF1R—trachea—esophageal cancer	0.00062	0.00562	CbGeAlD
Pazopanib—STK16—lymph node—esophageal cancer	0.000618	0.0056	CbGeAlD
Pazopanib—FGF1—lung—esophageal cancer	0.000617	0.00559	CbGeAlD
Pazopanib—KIT—smooth muscle tissue—esophageal cancer	0.000613	0.00556	CbGeAlD
Pazopanib—LCK—lung—esophageal cancer	0.000613	0.00555	CbGeAlD
Pazopanib—PDGFRB—bronchus—esophageal cancer	0.000612	0.00555	CbGeAlD
Pazopanib—STK10—digestive system—esophageal cancer	0.000612	0.00554	CbGeAlD
Pazopanib—TAOK3—digestive system—esophageal cancer	0.00061	0.00552	CbGeAlD
Pazopanib—RIOK2—lymph node—esophageal cancer	0.000609	0.00551	CbGeAlD
Pazopanib—PDGFRA—digestive system—esophageal cancer	0.000606	0.00549	CbGeAlD
Pazopanib—BMPR1B—lymph node—esophageal cancer	0.000603	0.00546	CbGeAlD
Pazopanib—PDGFRB—smooth muscle tissue—esophageal cancer	0.000599	0.00543	CbGeAlD
Pazopanib—FGFR2—lung—esophageal cancer	0.000583	0.00528	CbGeAlD
Pazopanib—Mucosal inflammation—Methotrexate—esophageal cancer	0.000581	0.00478	CcSEcCtD
Pazopanib—UGT1A1—digestive system—esophageal cancer	0.000578	0.00523	CbGeAlD
Pazopanib—Rash erythematous—Capecitabine—esophageal cancer	0.000564	0.00464	CcSEcCtD
Pazopanib—KIT—trachea—esophageal cancer	0.000563	0.0051	CbGeAlD
Pazopanib—Skin exfoliation—Cisplatin—esophageal cancer	0.000559	0.0046	CcSEcCtD
Pazopanib—Hepatotoxicity—Capecitabine—esophageal cancer	0.000559	0.0046	CcSEcCtD
Pazopanib—Skin ulcer—Capecitabine—esophageal cancer	0.000555	0.00457	CcSEcCtD
Pazopanib—PDGFRB—trachea—esophageal cancer	0.00055	0.00498	CbGeAlD
Pazopanib—STK36—lymph node—esophageal cancer	0.000547	0.00495	CbGeAlD
Pazopanib—KDR—digestive system—esophageal cancer	0.000547	0.00495	CbGeAlD
Pazopanib—FLT1—lung—esophageal cancer	0.00054	0.00489	CbGeAlD
Pazopanib—PI4KB—lymph node—esophageal cancer	0.000538	0.00488	CbGeAlD
Pazopanib—Myocardial ischaemia—Capecitabine—esophageal cancer	0.000537	0.00442	CcSEcCtD
Pazopanib—EPHB6—lung—esophageal cancer	0.000534	0.00483	CbGeAlD
Pazopanib—CSF1R—digestive system—esophageal cancer	0.000533	0.00483	CbGeAlD
Pazopanib—Rhinorrhoea—Capecitabine—esophageal cancer	0.000533	0.00439	CcSEcCtD
Pazopanib—Ageusia—Capecitabine—esophageal cancer	0.000533	0.00439	CcSEcCtD
Pazopanib—LIMK2—lymph node—esophageal cancer	0.000529	0.00479	CbGeAlD
Pazopanib—Polyp—Methotrexate—esophageal cancer	0.000528	0.00435	CcSEcCtD
Pazopanib—Deep vein thrombosis—Methotrexate—esophageal cancer	0.000528	0.00435	CcSEcCtD
Pazopanib—Dysphonia—Capecitabine—esophageal cancer	0.000525	0.00432	CcSEcCtD
Pazopanib—STK10—lung—esophageal cancer	0.000511	0.00463	CbGeAlD
Pazopanib—TAOK3—lung—esophageal cancer	0.000509	0.00461	CbGeAlD
Pazopanib—PDGFRA—lung—esophageal cancer	0.000506	0.00458	CbGeAlD
Pazopanib—Embolism—Methotrexate—esophageal cancer	0.000501	0.00412	CcSEcCtD
Pazopanib—Encephalopathy—Methotrexate—esophageal cancer	0.000501	0.00412	CcSEcCtD
Pazopanib—Nail disorder—Methotrexate—esophageal cancer	0.000496	0.00408	CcSEcCtD
Pazopanib—Proteinuria—Capecitabine—esophageal cancer	0.000491	0.00405	CcSEcCtD
Pazopanib—Protein urine present—Capecitabine—esophageal cancer	0.000485	0.00399	CcSEcCtD
Pazopanib—KIT—digestive system—esophageal cancer	0.000484	0.00439	CbGeAlD
Pazopanib—SLCO1B1—digestive system—esophageal cancer	0.000481	0.00436	CbGeAlD
Pazopanib—Cyst—Methotrexate—esophageal cancer	0.000481	0.00396	CcSEcCtD
Pazopanib—Skin discolouration—Capecitabine—esophageal cancer	0.000478	0.00394	CcSEcCtD
Pazopanib—Rectal haemorrhage—Capecitabine—esophageal cancer	0.000478	0.00394	CcSEcCtD
Pazopanib—FLT4—lymph node—esophageal cancer	0.000475	0.0043	CbGeAlD
Pazopanib—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.000475	0.00391	CcSEcCtD
Pazopanib—Oropharyngeal pain—Capecitabine—esophageal cancer	0.000475	0.00391	CcSEcCtD
Pazopanib—PDGFRB—digestive system—esophageal cancer	0.000473	0.00428	CbGeAlD
Pazopanib—PIP4K2C—lymph node—esophageal cancer	0.000472	0.00428	CbGeAlD
Pazopanib—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000469	0.00386	CcSEcCtD
Pazopanib—FGFR1—lymph node—esophageal cancer	0.000469	0.00424	CbGeAlD
Pazopanib—Haematemesis—Methotrexate—esophageal cancer	0.000463	0.00381	CcSEcCtD
Pazopanib—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000457	0.00376	CcSEcCtD
Pazopanib—KDR—lung—esophageal cancer	0.000456	0.00413	CbGeAlD
Pazopanib—MAP2K5—lung—esophageal cancer	0.000456	0.00413	CbGeAlD
Pazopanib—MAP3K2—lymph node—esophageal cancer	0.000448	0.00406	CbGeAlD
Pazopanib—CSF1R—lung—esophageal cancer	0.000446	0.00403	CbGeAlD
Pazopanib—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000434	0.00357	CcSEcCtD
Pazopanib—Hiccups—Capecitabine—esophageal cancer	0.000432	0.00355	CcSEcCtD
Pazopanib—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.000432	0.00355	CcSEcCtD
Pazopanib—Pulmonary embolism—Capecitabine—esophageal cancer	0.000432	0.00355	CcSEcCtD
Pazopanib—Blood pressure increased—Capecitabine—esophageal cancer	0.000432	0.00355	CcSEcCtD
Pazopanib—Hyponatraemia—Cisplatin—esophageal cancer	0.000427	0.00351	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000425	0.0035	CcSEcCtD
Pazopanib—FGF1—lymph node—esophageal cancer	0.000422	0.00382	CbGeAlD
Pazopanib—Melaena—Capecitabine—esophageal cancer	0.000422	0.00347	CcSEcCtD
Pazopanib—LCK—lymph node—esophageal cancer	0.000419	0.0038	CbGeAlD
Pazopanib—Hepatotoxicity—Methotrexate—esophageal cancer	0.000416	0.00343	CcSEcCtD
Pazopanib—Skin ulcer—Methotrexate—esophageal cancer	0.000413	0.0034	CcSEcCtD
Pazopanib—Skin exfoliation—Capecitabine—esophageal cancer	0.000412	0.00339	CcSEcCtD
Pazopanib—Face oedema—Cisplatin—esophageal cancer	0.00041	0.00338	CcSEcCtD
Pazopanib—KIT—lung—esophageal cancer	0.000405	0.00366	CbGeAlD
Pazopanib—Blood creatinine increased—Cisplatin—esophageal cancer	0.000398	0.00328	CcSEcCtD
Pazopanib—Dehydration—Cisplatin—esophageal cancer	0.000395	0.00326	CcSEcCtD
Pazopanib—PDGFRB—lung—esophageal cancer	0.000395	0.00358	CbGeAlD
Pazopanib—Mouth ulceration—Capecitabine—esophageal cancer	0.00039	0.00321	CcSEcCtD
Pazopanib—Breast disorder—Cisplatin—esophageal cancer	0.000384	0.00316	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000383	0.00315	CcSEcCtD
Pazopanib—Nasopharyngitis—Cisplatin—esophageal cancer	0.00038	0.00313	CcSEcCtD
Pazopanib—FLT1—lymph node—esophageal cancer	0.000369	0.00334	CbGeAlD
Pazopanib—Proteinuria—Methotrexate—esophageal cancer	0.000366	0.00301	CcSEcCtD
Pazopanib—EPHB6—lymph node—esophageal cancer	0.000365	0.00331	CbGeAlD
Pazopanib—Protein urine present—Methotrexate—esophageal cancer	0.000361	0.00297	CcSEcCtD
Pazopanib—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00036	0.00297	CcSEcCtD
Pazopanib—Pancreatitis—Cisplatin—esophageal cancer	0.00036	0.00297	CcSEcCtD
Pazopanib—Hepatic function abnormal—Capecitabine—esophageal cancer	0.000359	0.00295	CcSEcCtD
Pazopanib—Skin discolouration—Methotrexate—esophageal cancer	0.000356	0.00293	CcSEcCtD
Pazopanib—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.000353	0.00291	CcSEcCtD
Pazopanib—STK10—lymph node—esophageal cancer	0.00035	0.00317	CbGeAlD
Pazopanib—Hepatic failure—Capecitabine—esophageal cancer	0.000349	0.00287	CcSEcCtD
Pazopanib—TAOK3—lymph node—esophageal cancer	0.000348	0.00315	CbGeAlD
Pazopanib—PDGFRA—lymph node—esophageal cancer	0.000346	0.00313	CbGeAlD
Pazopanib—Hepatic enzyme increased—Methotrexate—esophageal cancer	0.00034	0.0028	CcSEcCtD
Pazopanib—Hot flush—Capecitabine—esophageal cancer	0.000335	0.00276	CcSEcCtD
Pazopanib—Menopausal symptoms—Capecitabine—esophageal cancer	0.000332	0.00273	CcSEcCtD
Pazopanib—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000323	0.00266	CcSEcCtD
Pazopanib—Pulmonary embolism—Methotrexate—esophageal cancer	0.000321	0.00265	CcSEcCtD
Pazopanib—Myocardial infarction—Cisplatin—esophageal cancer	0.000321	0.00264	CcSEcCtD
Pazopanib—Cardiac failure—Capecitabine—esophageal cancer	0.000321	0.00264	CcSEcCtD
Pazopanib—Lethargy—Capecitabine—esophageal cancer	0.00032	0.00263	CcSEcCtD
Pazopanib—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00032	0.00263	CcSEcCtD
Pazopanib—Stomatitis—Cisplatin—esophageal cancer	0.000319	0.00263	CcSEcCtD
Pazopanib—Hyponatraemia—Capecitabine—esophageal cancer	0.000315	0.00259	CcSEcCtD
Pazopanib—Melaena—Methotrexate—esophageal cancer	0.000314	0.00258	CcSEcCtD
Pazopanib—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000313	0.00258	CcSEcCtD
Pazopanib—KDR—lymph node—esophageal cancer	0.000312	0.00283	CbGeAlD
Pazopanib—MAP2K5—lymph node—esophageal cancer	0.000312	0.00283	CbGeAlD
Pazopanib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.00031	0.00255	CcSEcCtD
Pazopanib—Skin exfoliation—Methotrexate—esophageal cancer	0.000307	0.00253	CcSEcCtD
Pazopanib—CSF1R—lymph node—esophageal cancer	0.000305	0.00276	CbGeAlD
Pazopanib—Face oedema—Capecitabine—esophageal cancer	0.000303	0.00249	CcSEcCtD
Pazopanib—Bradycardia—Cisplatin—esophageal cancer	0.000299	0.00247	CcSEcCtD
Pazopanib—Blood creatinine increased—Capecitabine—esophageal cancer	0.000294	0.00242	CcSEcCtD
Pazopanib—Dehydration—Capecitabine—esophageal cancer	0.000291	0.0024	CcSEcCtD
Pazopanib—Mouth ulceration—Methotrexate—esophageal cancer	0.000291	0.00239	CcSEcCtD
Pazopanib—Urinary tract disorder—Cisplatin—esophageal cancer	0.00029	0.00239	CcSEcCtD
Pazopanib—Liver function test abnormal—Capecitabine—esophageal cancer	0.000289	0.00238	CcSEcCtD
Pazopanib—Connective tissue disorder—Cisplatin—esophageal cancer	0.000289	0.00238	CcSEcCtD
Pazopanib—Urethral disorder—Cisplatin—esophageal cancer	0.000288	0.00237	CcSEcCtD
Pazopanib—Dry skin—Capecitabine—esophageal cancer	0.000287	0.00237	CcSEcCtD
Pazopanib—Abdominal pain upper—Capecitabine—esophageal cancer	0.000286	0.00236	CcSEcCtD
Pazopanib—Breast disorder—Capecitabine—esophageal cancer	0.000283	0.00233	CcSEcCtD
Pazopanib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000282	0.00232	CcSEcCtD
Pazopanib—Nasopharyngitis—Capecitabine—esophageal cancer	0.00028	0.00231	CcSEcCtD
Pazopanib—KIT—lymph node—esophageal cancer	0.000277	0.00251	CbGeAlD
Pazopanib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000276	0.00228	CcSEcCtD
Pazopanib—Eye disorder—Cisplatin—esophageal cancer	0.000275	0.00226	CcSEcCtD
Pazopanib—Flushing—Cisplatin—esophageal cancer	0.000273	0.00225	CcSEcCtD
Pazopanib—Cardiac disorder—Cisplatin—esophageal cancer	0.000273	0.00225	CcSEcCtD
Pazopanib—Abdominal distension—Capecitabine—esophageal cancer	0.000273	0.00225	CcSEcCtD
Pazopanib—PDGFRB—lymph node—esophageal cancer	0.00027	0.00245	CbGeAlD
Pazopanib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000265	0.00218	CcSEcCtD
Pazopanib—Alopecia—Cisplatin—esophageal cancer	0.00026	0.00214	CcSEcCtD
Pazopanib—Hepatic failure—Methotrexate—esophageal cancer	0.00026	0.00214	CcSEcCtD
Pazopanib—Erythema—Cisplatin—esophageal cancer	0.000256	0.00211	CcSEcCtD
Pazopanib—Malnutrition—Cisplatin—esophageal cancer	0.000256	0.00211	CcSEcCtD
Pazopanib—CYP1A2—digestive system—esophageal cancer	0.000256	0.00232	CbGeAlD
Pazopanib—Neutropenia—Capecitabine—esophageal cancer	0.000253	0.00209	CcSEcCtD
Pazopanib—Flatulence—Cisplatin—esophageal cancer	0.000252	0.00208	CcSEcCtD
Pazopanib—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000247	0.00204	CcSEcCtD
Pazopanib—Muscle spasms—Cisplatin—esophageal cancer	0.000246	0.00203	CcSEcCtD
Pazopanib—Weight decreased—Capecitabine—esophageal cancer	0.000245	0.00202	CcSEcCtD
Pazopanib—Infestation NOS—Capecitabine—esophageal cancer	0.000242	0.00199	CcSEcCtD
Pazopanib—Infestation—Capecitabine—esophageal cancer	0.000242	0.00199	CcSEcCtD
Pazopanib—Vision blurred—Cisplatin—esophageal cancer	0.000241	0.00199	CcSEcCtD
Pazopanib—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000238	0.00196	CcSEcCtD
Pazopanib—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000238	0.00196	CcSEcCtD
Pazopanib—Lethargy—Methotrexate—esophageal cancer	0.000238	0.00196	CcSEcCtD
Pazopanib—Myocardial infarction—Capecitabine—esophageal cancer	0.000237	0.00195	CcSEcCtD
Pazopanib—Anaemia—Cisplatin—esophageal cancer	0.000237	0.00195	CcSEcCtD
Pazopanib—Stomatitis—Capecitabine—esophageal cancer	0.000235	0.00194	CcSEcCtD
Pazopanib—Jaundice—Capecitabine—esophageal cancer	0.000235	0.00194	CcSEcCtD
Pazopanib—Haematuria—Capecitabine—esophageal cancer	0.00023	0.0019	CcSEcCtD
Pazopanib—Leukopenia—Cisplatin—esophageal cancer	0.000229	0.00189	CcSEcCtD
Pazopanib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000228	0.00188	CcSEcCtD
Pazopanib—Epistaxis—Capecitabine—esophageal cancer	0.000228	0.00188	CcSEcCtD
Pazopanib—ABCG2—lung—esophageal cancer	0.000222	0.00201	CbGeAlD
Pazopanib—Bradycardia—Capecitabine—esophageal cancer	0.000221	0.00182	CcSEcCtD
Pazopanib—Myalgia—Cisplatin—esophageal cancer	0.000218	0.00179	CcSEcCtD
Pazopanib—Haemoglobin—Capecitabine—esophageal cancer	0.000218	0.00179	CcSEcCtD
Pazopanib—Haemorrhage—Capecitabine—esophageal cancer	0.000217	0.00179	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000216	0.00178	CcSEcCtD
Pazopanib—Hypoaesthesia—Capecitabine—esophageal cancer	0.000216	0.00178	CcSEcCtD
Pazopanib—Liver function test abnormal—Methotrexate—esophageal cancer	0.000215	0.00177	CcSEcCtD
Pazopanib—Urinary tract disorder—Capecitabine—esophageal cancer	0.000214	0.00176	CcSEcCtD
Pazopanib—CYP1A2—lung—esophageal cancer	0.000214	0.00194	CbGeAlD
Pazopanib—Oedema peripheral—Capecitabine—esophageal cancer	0.000214	0.00176	CcSEcCtD
Pazopanib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000213	0.00175	CcSEcCtD
Pazopanib—Urethral disorder—Capecitabine—esophageal cancer	0.000213	0.00175	CcSEcCtD
Pazopanib—Breast disorder—Methotrexate—esophageal cancer	0.000211	0.00174	CcSEcCtD
Pazopanib—Oedema—Cisplatin—esophageal cancer	0.000209	0.00172	CcSEcCtD
Pazopanib—Infection—Cisplatin—esophageal cancer	0.000208	0.00171	CcSEcCtD
Pazopanib—Nervous system disorder—Cisplatin—esophageal cancer	0.000205	0.00169	CcSEcCtD
Pazopanib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000205	0.00168	CcSEcCtD
Pazopanib—Skin disorder—Cisplatin—esophageal cancer	0.000203	0.00167	CcSEcCtD
Pazopanib—Eye disorder—Capecitabine—esophageal cancer	0.000203	0.00167	CcSEcCtD
Pazopanib—Hyperhidrosis—Cisplatin—esophageal cancer	0.000202	0.00166	CcSEcCtD
Pazopanib—Flushing—Capecitabine—esophageal cancer	0.000201	0.00166	CcSEcCtD
Pazopanib—Cardiac disorder—Capecitabine—esophageal cancer	0.000201	0.00166	CcSEcCtD
Pazopanib—Anorexia—Cisplatin—esophageal cancer	0.000199	0.00164	CcSEcCtD
Pazopanib—Pancreatitis—Methotrexate—esophageal cancer	0.000198	0.00163	CcSEcCtD
Pazopanib—Angiopathy—Capecitabine—esophageal cancer	0.000197	0.00162	CcSEcCtD
Pazopanib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000195	0.00161	CcSEcCtD
Pazopanib—Chills—Capecitabine—esophageal cancer	0.000195	0.0016	CcSEcCtD
Pazopanib—Alopecia—Capecitabine—esophageal cancer	0.000192	0.00158	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00019	0.00157	CcSEcCtD
Pazopanib—Mental disorder—Capecitabine—esophageal cancer	0.00019	0.00156	CcSEcCtD
Pazopanib—Erythema—Capecitabine—esophageal cancer	0.000189	0.00155	CcSEcCtD
Pazopanib—Malnutrition—Capecitabine—esophageal cancer	0.000189	0.00155	CcSEcCtD
Pazopanib—Neutropenia—Methotrexate—esophageal cancer	0.000189	0.00155	CcSEcCtD
Pazopanib—Paraesthesia—Cisplatin—esophageal cancer	0.000188	0.00154	CcSEcCtD
Pazopanib—Dyspnoea—Cisplatin—esophageal cancer	0.000186	0.00153	CcSEcCtD
Pazopanib—Flatulence—Capecitabine—esophageal cancer	0.000186	0.00153	CcSEcCtD
Pazopanib—CYP3A4—digestive system—esophageal cancer	0.000185	0.00168	CbGeAlD
Pazopanib—Dysgeusia—Capecitabine—esophageal cancer	0.000185	0.00152	CcSEcCtD
Pazopanib—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000184	0.00152	CcSEcCtD
Pazopanib—CYP2D6—digestive system—esophageal cancer	0.000182	0.00165	CbGeAlD
Pazopanib—Decreased appetite—Cisplatin—esophageal cancer	0.000182	0.0015	CcSEcCtD
Pazopanib—Muscle spasms—Capecitabine—esophageal cancer	0.000181	0.00149	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00018	0.00149	CcSEcCtD
Pazopanib—Infestation—Methotrexate—esophageal cancer	0.00018	0.00148	CcSEcCtD
Pazopanib—Infestation NOS—Methotrexate—esophageal cancer	0.00018	0.00148	CcSEcCtD
Pazopanib—Pain—Cisplatin—esophageal cancer	0.000179	0.00147	CcSEcCtD
Pazopanib—Vision blurred—Capecitabine—esophageal cancer	0.000178	0.00146	CcSEcCtD
Pazopanib—Stomatitis—Methotrexate—esophageal cancer	0.000175	0.00144	CcSEcCtD
Pazopanib—Anaemia—Capecitabine—esophageal cancer	0.000174	0.00144	CcSEcCtD
Pazopanib—ABCB1—epithelium—esophageal cancer	0.000172	0.00156	CbGeAlD
Pazopanib—Haematuria—Methotrexate—esophageal cancer	0.000171	0.00141	CcSEcCtD
Pazopanib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00017	0.0014	CcSEcCtD
Pazopanib—Epistaxis—Methotrexate—esophageal cancer	0.00017	0.0014	CcSEcCtD
Pazopanib—Syncope—Capecitabine—esophageal cancer	0.000169	0.00139	CcSEcCtD
Pazopanib—Leukopenia—Capecitabine—esophageal cancer	0.000169	0.00139	CcSEcCtD
Pazopanib—Loss of consciousness—Capecitabine—esophageal cancer	0.000166	0.00137	CcSEcCtD
Pazopanib—Cough—Capecitabine—esophageal cancer	0.000165	0.00136	CcSEcCtD
Pazopanib—Hypertension—Capecitabine—esophageal cancer	0.000163	0.00134	CcSEcCtD
Pazopanib—Haemoglobin—Methotrexate—esophageal cancer	0.000162	0.00134	CcSEcCtD
Pazopanib—Haemorrhage—Methotrexate—esophageal cancer	0.000161	0.00133	CcSEcCtD
Pazopanib—Chest pain—Capecitabine—esophageal cancer	0.000161	0.00132	CcSEcCtD
Pazopanib—Myalgia—Capecitabine—esophageal cancer	0.000161	0.00132	CcSEcCtD
Pazopanib—Arthralgia—Capecitabine—esophageal cancer	0.000161	0.00132	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00016	0.00131	CcSEcCtD
Pazopanib—Urinary tract disorder—Methotrexate—esophageal cancer	0.000159	0.00131	CcSEcCtD
Pazopanib—Urethral disorder—Methotrexate—esophageal cancer	0.000158	0.0013	CcSEcCtD
Pazopanib—Dry mouth—Capecitabine—esophageal cancer	0.000157	0.00129	CcSEcCtD
Pazopanib—Oedema—Capecitabine—esophageal cancer	0.000154	0.00127	CcSEcCtD
Pazopanib—Infection—Capecitabine—esophageal cancer	0.000153	0.00126	CcSEcCtD
Pazopanib—ABCB1—trachea—esophageal cancer	0.000152	0.00138	CbGeAlD
Pazopanib—ABCG2—lymph node—esophageal cancer	0.000152	0.00138	CbGeAlD
Pazopanib—Shock—Capecitabine—esophageal cancer	0.000152	0.00125	CcSEcCtD
Pazopanib—Nervous system disorder—Capecitabine—esophageal cancer	0.000151	0.00124	CcSEcCtD
Pazopanib—Eye disorder—Methotrexate—esophageal cancer	0.000151	0.00124	CcSEcCtD
Pazopanib—Thrombocytopenia—Capecitabine—esophageal cancer	0.000151	0.00124	CcSEcCtD
Pazopanib—Asthenia—Cisplatin—esophageal cancer	0.00015	0.00123	CcSEcCtD
Pazopanib—Cardiac disorder—Methotrexate—esophageal cancer	0.00015	0.00123	CcSEcCtD
Pazopanib—Skin disorder—Capecitabine—esophageal cancer	0.00015	0.00123	CcSEcCtD
Pazopanib—Hyperhidrosis—Capecitabine—esophageal cancer	0.000149	0.00123	CcSEcCtD
Pazopanib—Anorexia—Capecitabine—esophageal cancer	0.000147	0.00121	CcSEcCtD
Pazopanib—Angiopathy—Methotrexate—esophageal cancer	0.000146	0.00121	CcSEcCtD
Pazopanib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000145	0.0012	CcSEcCtD
Pazopanib—Chills—Methotrexate—esophageal cancer	0.000145	0.00119	CcSEcCtD
Pazopanib—Diarrhoea—Cisplatin—esophageal cancer	0.000143	0.00118	CcSEcCtD
Pazopanib—Alopecia—Methotrexate—esophageal cancer	0.000143	0.00117	CcSEcCtD
Pazopanib—Mental disorder—Methotrexate—esophageal cancer	0.000141	0.00116	CcSEcCtD
Pazopanib—Erythema—Methotrexate—esophageal cancer	0.000141	0.00116	CcSEcCtD
Pazopanib—Malnutrition—Methotrexate—esophageal cancer	0.000141	0.00116	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.00014	0.00116	CcSEcCtD
Pazopanib—Insomnia—Capecitabine—esophageal cancer	0.000139	0.00115	CcSEcCtD
Pazopanib—Paraesthesia—Capecitabine—esophageal cancer	0.000138	0.00114	CcSEcCtD
Pazopanib—Dysgeusia—Methotrexate—esophageal cancer	0.000138	0.00113	CcSEcCtD
Pazopanib—Dyspnoea—Capecitabine—esophageal cancer	0.000137	0.00113	CcSEcCtD
Pazopanib—Dyspepsia—Capecitabine—esophageal cancer	0.000136	0.00112	CcSEcCtD
Pazopanib—Decreased appetite—Capecitabine—esophageal cancer	0.000134	0.0011	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000133	0.00109	CcSEcCtD
Pazopanib—Vomiting—Cisplatin—esophageal cancer	0.000133	0.00109	CcSEcCtD
Pazopanib—Fatigue—Capecitabine—esophageal cancer	0.000133	0.00109	CcSEcCtD
Pazopanib—Vision blurred—Methotrexate—esophageal cancer	0.000132	0.00109	CcSEcCtD
Pazopanib—Rash—Cisplatin—esophageal cancer	0.000132	0.00108	CcSEcCtD
Pazopanib—Pain—Capecitabine—esophageal cancer	0.000132	0.00108	CcSEcCtD
Pazopanib—Dermatitis—Cisplatin—esophageal cancer	0.000132	0.00108	CcSEcCtD
Pazopanib—ABCB1—digestive system—esophageal cancer	0.000131	0.00119	CbGeAlD
Pazopanib—Anaemia—Methotrexate—esophageal cancer	0.00013	0.00107	CcSEcCtD
Pazopanib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000126	0.00104	CcSEcCtD
Pazopanib—Leukopenia—Methotrexate—esophageal cancer	0.000126	0.00104	CcSEcCtD
Pazopanib—Nausea—Cisplatin—esophageal cancer	0.000124	0.00102	CcSEcCtD
Pazopanib—Cough—Methotrexate—esophageal cancer	0.000123	0.00101	CcSEcCtD
Pazopanib—Abdominal pain—Capecitabine—esophageal cancer	0.000122	0.001	CcSEcCtD
Pazopanib—Chest pain—Methotrexate—esophageal cancer	0.00012	0.000985	CcSEcCtD
Pazopanib—Arthralgia—Methotrexate—esophageal cancer	0.00012	0.000985	CcSEcCtD
Pazopanib—Myalgia—Methotrexate—esophageal cancer	0.00012	0.000985	CcSEcCtD
Pazopanib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000119	0.000978	CcSEcCtD
Pazopanib—Infection—Methotrexate—esophageal cancer	0.000114	0.000938	CcSEcCtD
Pazopanib—Nervous system disorder—Methotrexate—esophageal cancer	0.000112	0.000926	CcSEcCtD
Pazopanib—Thrombocytopenia—Methotrexate—esophageal cancer	0.000112	0.000924	CcSEcCtD
Pazopanib—Skin disorder—Methotrexate—esophageal cancer	0.000111	0.000917	CcSEcCtD
Pazopanib—Hyperhidrosis—Methotrexate—esophageal cancer	0.000111	0.000913	CcSEcCtD
Pazopanib—Asthenia—Capecitabine—esophageal cancer	0.000111	0.00091	CcSEcCtD
Pazopanib—ABCB1—lung—esophageal cancer	0.00011	0.000992	CbGeAlD
Pazopanib—Anorexia—Methotrexate—esophageal cancer	0.000109	0.0009	CcSEcCtD
Pazopanib—Pruritus—Capecitabine—esophageal cancer	0.000109	0.000897	CcSEcCtD
Pazopanib—Diarrhoea—Capecitabine—esophageal cancer	0.000105	0.000868	CcSEcCtD
Pazopanib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000104	0.00086	CcSEcCtD
Pazopanib—Insomnia—Methotrexate—esophageal cancer	0.000104	0.000854	CcSEcCtD
Pazopanib—Paraesthesia—Methotrexate—esophageal cancer	0.000103	0.000848	CcSEcCtD
Pazopanib—Dyspnoea—Methotrexate—esophageal cancer	0.000102	0.000842	CcSEcCtD
Pazopanib—Somnolence—Methotrexate—esophageal cancer	0.000102	0.000839	CcSEcCtD
Pazopanib—Dizziness—Capecitabine—esophageal cancer	0.000102	0.000839	CcSEcCtD
Pazopanib—Dyspepsia—Methotrexate—esophageal cancer	0.000101	0.000831	CcSEcCtD
Pazopanib—Decreased appetite—Methotrexate—esophageal cancer	9.97e-05	0.000821	CcSEcCtD
Pazopanib—Gastrointestinal disorder—Methotrexate—esophageal cancer	9.9e-05	0.000815	CcSEcCtD
Pazopanib—Fatigue—Methotrexate—esophageal cancer	9.89e-05	0.000814	CcSEcCtD
Pazopanib—Pain—Methotrexate—esophageal cancer	9.81e-05	0.000807	CcSEcCtD
Pazopanib—Vomiting—Capecitabine—esophageal cancer	9.79e-05	0.000806	CcSEcCtD
Pazopanib—Rash—Capecitabine—esophageal cancer	9.71e-05	0.0008	CcSEcCtD
Pazopanib—Dermatitis—Capecitabine—esophageal cancer	9.7e-05	0.000799	CcSEcCtD
Pazopanib—Headache—Capecitabine—esophageal cancer	9.65e-05	0.000795	CcSEcCtD
Pazopanib—Gastrointestinal pain—Methotrexate—esophageal cancer	9.38e-05	0.000772	CcSEcCtD
Pazopanib—Nausea—Capecitabine—esophageal cancer	9.15e-05	0.000753	CcSEcCtD
Pazopanib—Abdominal pain—Methotrexate—esophageal cancer	9.07e-05	0.000746	CcSEcCtD
Pazopanib—Asthenia—Methotrexate—esophageal cancer	8.23e-05	0.000677	CcSEcCtD
Pazopanib—Pruritus—Methotrexate—esophageal cancer	8.11e-05	0.000668	CcSEcCtD
Pazopanib—Diarrhoea—Methotrexate—esophageal cancer	7.85e-05	0.000646	CcSEcCtD
Pazopanib—Dizziness—Methotrexate—esophageal cancer	7.58e-05	0.000624	CcSEcCtD
Pazopanib—ABCB1—lymph node—esophageal cancer	7.49e-05	0.000678	CbGeAlD
Pazopanib—Vomiting—Methotrexate—esophageal cancer	7.29e-05	0.0006	CcSEcCtD
Pazopanib—Rash—Methotrexate—esophageal cancer	7.23e-05	0.000595	CcSEcCtD
Pazopanib—Dermatitis—Methotrexate—esophageal cancer	7.22e-05	0.000595	CcSEcCtD
Pazopanib—Headache—Methotrexate—esophageal cancer	7.18e-05	0.000591	CcSEcCtD
Pazopanib—Nausea—Methotrexate—esophageal cancer	6.81e-05	0.000561	CcSEcCtD
Pazopanib—FLT1—Signaling Pathways—TP53—esophageal cancer	3.73e-06	1.99e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—CDKN1A—esophageal cancer	3.73e-06	1.99e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NOTCH1—esophageal cancer	3.72e-06	1.98e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—CREBBP—esophageal cancer	3.69e-06	1.97e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GAPDH—esophageal cancer	3.67e-06	1.96e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—CDKN1A—esophageal cancer	3.65e-06	1.95e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—CDKN1A—esophageal cancer	3.65e-06	1.94e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—EP300—esophageal cancer	3.65e-06	1.94e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—GSTT1—esophageal cancer	3.64e-06	1.94e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NOTCH1—esophageal cancer	3.64e-06	1.94e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—EP300—esophageal cancer	3.64e-06	1.94e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CRABP1—esophageal cancer	3.64e-06	1.94e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—ENO1—esophageal cancer	3.62e-06	1.93e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS1—esophageal cancer	3.62e-06	1.93e-05	CbGpPWpGaD
Pazopanib—LCK—Innate Immune System—PIK3CA—esophageal cancer	3.62e-06	1.93e-05	CbGpPWpGaD
Pazopanib—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.62e-06	1.93e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—EGFR—esophageal cancer	3.61e-06	1.92e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—BCL2—esophageal cancer	3.6e-06	1.92e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—NOS3—esophageal cancer	3.6e-06	1.92e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP2A6—esophageal cancer	3.6e-06	1.92e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CCND1—esophageal cancer	3.6e-06	1.92e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.57e-06	1.9e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PSME2—esophageal cancer	3.57e-06	1.9e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PSME1—esophageal cancer	3.57e-06	1.9e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EP300—esophageal cancer	3.56e-06	1.9e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ADH1B—esophageal cancer	3.55e-06	1.89e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—EP300—esophageal cancer	3.55e-06	1.89e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—EGFR—esophageal cancer	3.55e-06	1.89e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—NOS3—esophageal cancer	3.54e-06	1.89e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CYP1B1—esophageal cancer	3.53e-06	1.88e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—ERBB2—esophageal cancer	3.5e-06	1.87e-05	CbGpPWpGaD
Pazopanib—FGF1—Disease—PIK3CA—esophageal cancer	3.5e-06	1.86e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—CDKN1A—esophageal cancer	3.48e-06	1.85e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EP300—esophageal cancer	3.47e-06	1.85e-05	CbGpPWpGaD
Pazopanib—LCK—Adaptive Immune System—PIK3CA—esophageal cancer	3.47e-06	1.85e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—MYC—esophageal cancer	3.47e-06	1.85e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EP300—esophageal cancer	3.47e-06	1.85e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GNG7—esophageal cancer	3.46e-06	1.84e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—NOS3—esophageal cancer	3.46e-06	1.84e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—CDKN1A—esophageal cancer	3.44e-06	1.84e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ENO1—esophageal cancer	3.41e-06	1.82e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS1—esophageal cancer	3.41e-06	1.82e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—MYC—esophageal cancer	3.41e-06	1.82e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—EGFR—esophageal cancer	3.39e-06	1.81e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TYMP—esophageal cancer	3.39e-06	1.81e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—CREBBP—esophageal cancer	3.38e-06	1.8e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CREBBP—esophageal cancer	3.37e-06	1.8e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—ERBB2—esophageal cancer	3.37e-06	1.8e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—EGFR—esophageal cancer	3.37e-06	1.79e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PSME1—esophageal cancer	3.36e-06	1.79e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PSME2—esophageal cancer	3.36e-06	1.79e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—EGFR—esophageal cancer	3.36e-06	1.79e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—NOS3—esophageal cancer	3.36e-06	1.79e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—NOS3—esophageal cancer	3.35e-06	1.78e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—MYC—esophageal cancer	3.35e-06	1.78e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—EGFR—esophageal cancer	3.33e-06	1.78e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CYP19A1—esophageal cancer	3.32e-06	1.77e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EP300—esophageal cancer	3.31e-06	1.76e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—HIF1A—esophageal cancer	3.31e-06	1.76e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—ERBB2—esophageal cancer	3.31e-06	1.76e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—NOS3—esophageal cancer	3.31e-06	1.76e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.3e-06	1.76e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CREBBP—esophageal cancer	3.3e-06	1.76e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EP300—esophageal cancer	3.28e-06	1.75e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—EGFR—esophageal cancer	3.27e-06	1.75e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ALDH2—esophageal cancer	3.24e-06	1.73e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—ERBB2—esophageal cancer	3.23e-06	1.72e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.22e-06	1.71e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—MYC—esophageal cancer	3.18e-06	1.69e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—MYC—esophageal cancer	3.17e-06	1.69e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—KDR—esophageal cancer	3.17e-06	1.69e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PTGS2—esophageal cancer	3.16e-06	1.68e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—ERBB2—esophageal cancer	3.14e-06	1.67e-05	CbGpPWpGaD
Pazopanib—FGFR2—Immune System—PIK3CA—esophageal cancer	3.13e-06	1.67e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—CREBBP—esophageal cancer	3.13e-06	1.67e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—ERBB2—esophageal cancer	3.13e-06	1.67e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—EGFR—esophageal cancer	3.11e-06	1.66e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—MYC—esophageal cancer	3.1e-06	1.65e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—EGFR—esophageal cancer	3.1e-06	1.65e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—GSTT1—esophageal cancer	3.08e-06	1.64e-05	CbGpPWpGaD
Pazopanib—KIT—Immune System—PIK3CA—esophageal cancer	3.08e-06	1.64e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP1B1—esophageal cancer	3.08e-06	1.64e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTO1—esophageal cancer	3.07e-06	1.64e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—TPI1—esophageal cancer	3.07e-06	1.64e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP2A6—esophageal cancer	3.05e-06	1.62e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.04e-06	1.62e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—EGFR—esophageal cancer	3.03e-06	1.62e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—HMOX1—esophageal cancer	3.03e-06	1.61e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—NOS3—esophageal cancer	3.03e-06	1.61e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—EGFR—esophageal cancer	3.02e-06	1.61e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—MYC—esophageal cancer	3.02e-06	1.61e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PTGS2—esophageal cancer	3.02e-06	1.61e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—NOS3—esophageal cancer	3.02e-06	1.61e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—CDKN1A—esophageal cancer	2.99e-06	1.6e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NOTCH1—esophageal cancer	2.98e-06	1.59e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CCND1—esophageal cancer	2.98e-06	1.59e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.97e-06	1.58e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—EGFR—esophageal cancer	2.96e-06	1.58e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—EGFR—esophageal cancer	2.96e-06	1.58e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—NOS3—esophageal cancer	2.95e-06	1.57e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—PIK3CA—esophageal cancer	2.95e-06	1.57e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALDOB—esophageal cancer	2.94e-06	1.57e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CCND1—esophageal cancer	2.92e-06	1.56e-05	CbGpPWpGaD
Pazopanib—FGFR1—Immune System—PIK3CA—esophageal cancer	2.92e-06	1.56e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Immune System—PIK3CA—esophageal cancer	2.91e-06	1.55e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—ABCB1—esophageal cancer	2.91e-06	1.55e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP1B1—esophageal cancer	2.9e-06	1.55e-05	CbGpPWpGaD
Pazopanib—FGFR2—Disease—PIK3CA—esophageal cancer	2.89e-06	1.54e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CYP19A1—esophageal cancer	2.89e-06	1.54e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS1—esophageal cancer	2.89e-06	1.54e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ENO1—esophageal cancer	2.89e-06	1.54e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—MYC—esophageal cancer	2.88e-06	1.54e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—CDKN1A—esophageal cancer	2.88e-06	1.53e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—MYC—esophageal cancer	2.86e-06	1.52e-05	CbGpPWpGaD
Pazopanib—FGFR3—Signaling Pathways—TP53—esophageal cancer	2.85e-06	1.52e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EP300—esophageal cancer	2.85e-06	1.52e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PSME1—esophageal cancer	2.85e-06	1.52e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PSME2—esophageal cancer	2.85e-06	1.52e-05	CbGpPWpGaD
Pazopanib—KIT—Disease—PIK3CA—esophageal cancer	2.84e-06	1.51e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GAPDH—esophageal cancer	2.83e-06	1.51e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—CDKN1A—esophageal cancer	2.83e-06	1.51e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—EGFR—esophageal cancer	2.82e-06	1.5e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—ERBB2—esophageal cancer	2.82e-06	1.5e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.81e-06	1.5e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—NOS3—esophageal cancer	2.8e-06	1.49e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—EGFR—esophageal cancer	2.79e-06	1.49e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CCND1—esophageal cancer	2.77e-06	1.48e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PTGS2—esophageal cancer	2.77e-06	1.48e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CCND1—esophageal cancer	2.77e-06	1.47e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—CDKN1A—esophageal cancer	2.76e-06	1.47e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—ERBB2—esophageal cancer	2.76e-06	1.47e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EP300—esophageal cancer	2.74e-06	1.46e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.73e-06	1.45e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CREBBP—esophageal cancer	2.7e-06	1.44e-05	CbGpPWpGaD
Pazopanib—FGFR1—Disease—PIK3CA—esophageal cancer	2.7e-06	1.44e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EP300—esophageal cancer	2.69e-06	1.43e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Disease—PIK3CA—esophageal cancer	2.69e-06	1.43e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—CDKN1A—esophageal cancer	2.68e-06	1.43e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—CDKN1A—esophageal cancer	2.68e-06	1.43e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GNG7—esophageal cancer	2.67e-06	1.42e-05	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—HMOX1—esophageal cancer	2.64e-06	1.41e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—PIK3CA—esophageal cancer	2.63e-06	1.4e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EP300—esophageal cancer	2.63e-06	1.4e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Immune System—PIK3CA—esophageal cancer	2.63e-06	1.4e-05	CbGpPWpGaD
Pazopanib—LYN—Immune System—PIK3CA—esophageal cancer	2.57e-06	1.37e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—PIK3CA—esophageal cancer	2.57e-06	1.37e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PTGS2—esophageal cancer	2.56e-06	1.37e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EP300—esophageal cancer	2.55e-06	1.36e-05	CbGpPWpGaD
Pazopanib—MAP2K5—Signaling Pathways—TP53—esophageal cancer	2.55e-06	1.36e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EP300—esophageal cancer	2.55e-06	1.36e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—EP300—esophageal cancer	2.51e-06	1.34e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.5e-06	1.33e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CCND1—esophageal cancer	2.49e-06	1.33e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—HMOX1—esophageal cancer	2.49e-06	1.33e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.49e-06	1.32e-05	CbGpPWpGaD
Pazopanib—KDR—Signaling Pathways—TP53—esophageal cancer	2.48e-06	1.32e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP1B1—esophageal cancer	2.46e-06	1.31e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—PIK3CA—esophageal cancer	2.45e-06	1.31e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CCND1—esophageal cancer	2.44e-06	1.3e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—EGFR—esophageal cancer	2.43e-06	1.29e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Disease—PIK3CA—esophageal cancer	2.42e-06	1.29e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—NOS3—esophageal cancer	2.42e-06	1.29e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—CDKN1A—esophageal cancer	2.41e-06	1.29e-05	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—ABCB1—esophageal cancer	2.39e-06	1.27e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—MYC—esophageal cancer	2.39e-06	1.27e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.38e-06	1.27e-05	CbGpPWpGaD
Pazopanib—FGF1—Signaling Pathways—TP53—esophageal cancer	2.37e-06	1.26e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—CDKN1A—esophageal cancer	2.36e-06	1.26e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.35e-06	1.25e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—MYC—esophageal cancer	2.34e-06	1.25e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—EGFR—esophageal cancer	2.33e-06	1.24e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CYP19A1—esophageal cancer	2.31e-06	1.23e-05	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—EP300—esophageal cancer	2.3e-06	1.23e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EP300—esophageal cancer	2.29e-06	1.22e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—EGFR—esophageal cancer	2.29e-06	1.22e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—MYC—esophageal cancer	2.29e-06	1.22e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—ERBB2—esophageal cancer	2.26e-06	1.21e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EP300—esophageal cancer	2.25e-06	1.2e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—EGFR—esophageal cancer	2.24e-06	1.19e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ENO1—esophageal cancer	2.23e-06	1.19e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.23e-06	1.19e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—MYC—esophageal cancer	2.23e-06	1.19e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—MYC—esophageal cancer	2.22e-06	1.18e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.2e-06	1.17e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PSME1—esophageal cancer	2.2e-06	1.17e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PSME2—esophageal cancer	2.2e-06	1.17e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—EGFR—esophageal cancer	2.18e-06	1.16e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—EGFR—esophageal cancer	2.17e-06	1.16e-05	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—EP300—esophageal cancer	2.13e-06	1.14e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—HMOX1—esophageal cancer	2.11e-06	1.12e-05	CbGpPWpGaD
Pazopanib—LCK—Immune System—PIK3CA—esophageal cancer	2.11e-06	1.12e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.07e-06	1.1e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—PIK3CA—esophageal cancer	2.03e-06	1.08e-05	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—ABCB1—esophageal cancer	2.02e-06	1.08e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CCND1—esophageal cancer	2e-06	1.07e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—MYC—esophageal cancer	2e-06	1.07e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—PIK3CA—esophageal cancer	1.99e-06	1.06e-05	CbGpPWpGaD
Pazopanib—FGFR2—Signaling Pathways—TP53—esophageal cancer	1.96e-06	1.04e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—MYC—esophageal cancer	1.96e-06	1.04e-05	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—EGFR—esophageal cancer	1.96e-06	1.04e-05	CbGpPWpGaD
Pazopanib—LCK—Disease—PIK3CA—esophageal cancer	1.95e-06	1.04e-05	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—CREBBP—esophageal cancer	1.94e-06	1.04e-05	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—CDKN1A—esophageal cancer	1.94e-06	1.03e-05	CbGpPWpGaD
Pazopanib—KIT—Signaling Pathways—TP53—esophageal cancer	1.93e-06	1.03e-05	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—EGFR—esophageal cancer	1.91e-06	1.02e-05	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	1.9e-06	1.01e-05	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—PIK3CA—esophageal cancer	1.89e-06	1.01e-05	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—PIK3CA—esophageal cancer	1.88e-06	1e-05	CbGpPWpGaD
Pazopanib—UGT1A1—Metabolism—PIK3CA—esophageal cancer	1.86e-06	9.91e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EP300—esophageal cancer	1.84e-06	9.81e-06	CbGpPWpGaD
Pazopanib—FGFR1—Signaling Pathways—TP53—esophageal cancer	1.83e-06	9.74e-06	CbGpPWpGaD
Pazopanib—PDGFRA—Signaling Pathways—TP53—esophageal cancer	1.82e-06	9.71e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.78e-06	9.5e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—NOS3—esophageal cancer	1.74e-06	9.28e-06	CbGpPWpGaD
Pazopanib—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	1.7e-06	9.08e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—PIK3CA—esophageal cancer	1.7e-06	9.05e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—CREBBP—esophageal cancer	1.69e-06	9.03e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—PIK3CA—esophageal cancer	1.66e-06	8.86e-06	CbGpPWpGaD
Pazopanib—PDGFRB—Signaling Pathways—TP53—esophageal cancer	1.64e-06	8.75e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.63e-06	8.67e-06	CbGpPWpGaD
Pazopanib—LYN—Signaling Pathways—TP53—esophageal cancer	1.61e-06	8.57e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—MYC—esophageal cancer	1.6e-06	8.55e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.6e-06	8.5e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PTGS2—esophageal cancer	1.59e-06	8.48e-06	CbGpPWpGaD
Pazopanib—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.58e-06	8.41e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—EGFR—esophageal cancer	1.57e-06	8.36e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.56e-06	8.32e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.53e-06	8.15e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—NOS3—esophageal cancer	1.52e-06	8.08e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—NOS3—esophageal cancer	1.43e-06	7.61e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PTGS2—esophageal cancer	1.39e-06	7.39e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—PIK3CA—esophageal cancer	1.36e-06	7.26e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—CREBBP—esophageal cancer	1.35e-06	7.2e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—EP300—esophageal cancer	1.32e-06	7.06e-06	CbGpPWpGaD
Pazopanib—LCK—Signaling Pathways—TP53—esophageal cancer	1.32e-06	7.02e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.31e-06	6.96e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—NOS3—esophageal cancer	1.21e-06	6.45e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—EP300—esophageal cancer	1.15e-06	6.15e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PTGS2—esophageal cancer	1.11e-06	5.9e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—EP300—esophageal cancer	1.09e-06	5.79e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.04e-06	5.56e-06	CbGpPWpGaD
Pazopanib—CYP2C8—Metabolism—PIK3CA—esophageal cancer	9.79e-07	5.22e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—NOS3—esophageal cancer	9.34e-07	4.98e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—EP300—esophageal cancer	9.21e-07	4.91e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PTGS2—esophageal cancer	8.54e-07	4.55e-06	CbGpPWpGaD
Pazopanib—ABCB1—Metabolism—PIK3CA—esophageal cancer	8.53e-07	4.55e-06	CbGpPWpGaD
Pazopanib—CYP2D6—Metabolism—PIK3CA—esophageal cancer	8.04e-07	4.28e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—EP300—esophageal cancer	7.11e-07	3.79e-06	CbGpPWpGaD
Pazopanib—CYP1A2—Metabolism—PIK3CA—esophageal cancer	6.81e-07	3.63e-06	CbGpPWpGaD
Pazopanib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	5.26e-07	2.8e-06	CbGpPWpGaD
